ziresovir

respiratory syncytial virus (RSV) fusion (F) protein inhibitor

Also Known As:

AK-0529; AK0529; N-((3-aminooxetan-3-yl)methyl)-2-(1,1-dioxo-3,5-dihydro-2H-1lambda6,4-benzothiazepin-4-yl)-6-methylquinazolin-4-amine; RO-0529; RO0529

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azepines: 11
    - Thiazepines: 6
      - ziresovir: 4
  - Thiepins
    - Thiazepines: 6
      - ziresovir: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - ziresovir: 4
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfones: 534
    - ziresovir: 4
  - Thiepins
    - Thiazepines: 6
      - ziresovir: 4

Experts

1.	Beigel, John H: 2 articles (01/2019 - 01/2018)
2.	Chen, Li: 1 article (11/2019)
3.	Feng, Song: 1 article (11/2019)
4.	Gao, Lu: 1 article (11/2019)
5.	Guo, Tao: 1 article (11/2019)
6.	Liang, Chungen: 1 article (11/2019)
7.	Liu, Yongfu: 1 article (11/2019)
8.	Shen, Hong C: 1 article (11/2019)
9.	Wang, Baoxia: 1 article (11/2019)
10.	Wang, Lisha: 1 article (11/2019)

Related Diseases

1.	Human Influenza (Influenza) 01/01/2018 - "Updates were presented on several therapeutics currently in clinical trials, including influenza polymerase inhibitors pimodivir/JNJ6362387, S033188, favipiravir, monoclonal antibodies MHAA45449A and VIS410, and host directed strategies for influenza including nitazoxanide, and polymerase ALS-008112 and fusion inhibitors AK0529, GS-5806 for RSV. " 01/01/2019 - "Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. "
2.	Respiratory Syncytial Virus Infections 01/01/2023 - "This was a Phase 2 study of the oral RSV fusion protein inhibitor AK0529 in infants aged 1-24 months, hospitalized with RSV infection. "
3.	Virus Diseases (Viral Diseases) 11/01/2019 - "RO-0529 demonstrates single-digit nM EC50 potency against laboratory strains, as well as clinical isolates of RSV in cellular assays, and more than one log viral load reduction in BALB/c mouse model of RSV viral infection. "

Related Drugs and Biologics

1.	favipiravir
2.	nitazoxanide (NTZ)
3.	pimodivir
4.	presatovir
5.	Proteins (Proteins, Gene)
6.	Monoclonal Antibodies
7.	ziresovir
8.	Immunoglobulins (Immunoglobulin)
9.	Diltiazem (Cardizem)
10.	Antiviral Agents (Antivirals)

Related Therapies and Procedures

1.	Therapeutics